Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Phase 1
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 24
- Registration Number
- NCT03422393
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Michael Choi
- Target Recruit Count
- 2
- Registration Number
- NCT02784834
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Phase 1
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Michael Choi
- Registration Number
- NCT02611908
© Copyright 2025. All Rights Reserved by MedPath